GT Biopharma Inc (GTBP)

$0.32 -0.02 (-5.92%)
Market Cap 12.22M
Revenue (ttm) 0.00
Net Income (ttm) -28.35M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 606,700
Avg Vol 683,182
Day's Range N/A - N/A
Shares Out 35.62M
Stochastic %K 35%
Beta 0.64
Analysts Sell
Price Target $3.00

Company Profile

GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, that is in phase 1 dose escalation basket trial that targets B7-H3 on the surface of advanced solid tumo...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 919 4040
Address:
315 Montgomery Street, 10th Floor, San Francisco, United States
Investing4Knowledge
Investing4Knowledge May. 5 at 1:53 PM
$SRXH - those who wait will be rewarded here, just like $GTBP which was dormant and now finally taking up the last couple days
1 · Reply
princedazzler
princedazzler May. 4 at 5:44 PM
$GTBP Has great volume Should rip sometime soon Wuld be great to rip to $14
1 · Reply
Sidd_F
Sidd_F May. 4 at 5:36 PM
$GTBP if you've ever been curious about Cataldo's abrupt departure... https://hannahhowell.com/anthony-cataldo-stole-3-2m-from-gt-biopharma-to-fund-his-beverly-hills-mansion/
1 · Reply
vesti
vesti May. 4 at 4:52 PM
$GTBP Probably shorties margin calls.
0 · Reply
WallStreetVice
WallStreetVice May. 3 at 7:26 PM
$GTBP Need a bounce to 1$
0 · Reply
BillionerOfKing
BillionerOfKing May. 2 at 12:39 AM
$GTBP Current Stock Price: $0.34
0 · Reply
Zulu72
Zulu72 May. 1 at 2:12 PM
$GTBP first decent price action in weeks ... cant find any news ... anybody know anything? 😬
0 · Reply
Investing4Knowledge
Investing4Knowledge Apr. 27 at 6:34 PM
$GTBP - crazy sell off for zero reason. Looking forward to the company releasing PR updates here. If everything goes as planned, I could see this getting back to $0.80-$1.00 range
1 · Reply
vesti
vesti Apr. 24 at 3:45 PM
$GTBP upgraded to buy by Zacks https://www.zacks.com/stock/news/2884714/gt-biopharma-gtbp-upgraded-to-buy-here-s-what-you-should-know?cid=CS-STOCKTWITS-HL-tale_of_the_tape|yseop_template_12_zacks_rank_upgrade-2884714&adid=SYND_STOCKTWITS_HEADLINE_TALEOFTHETAPE_523_2884714
0 · Reply
focafoca99
focafoca99 Apr. 7 at 9:12 PM
$GTBP entered an investigator-sponsored clinical-trial agreement with the University of Minnesota for GTB-5550 worth up to about $3.8 million over three years.
0 · Reply
Latest News on GTBP
GT Biopharma files to sell 9.72M shares of common stock for holders

2026-04-30T21:13:17.000Z - 12 days ago

GT Biopharma files to sell 9.72M shares of common stock for holders

GT Biopharma Transcript: Biotech Resurgence: Platforms and Pipelines of Today's Innovators

Apr 16, 2026, 2:00 PM EDT - 26 days ago

GT Biopharma Transcript: Biotech Resurgence: Platforms and Pipelines of Today's Innovators

GT Biopharma price target lowered to $3 from $8 at Roth Capital

2026-03-03T13:31:45.000Z - 2 months ago

GT Biopharma price target lowered to $3 from $8 at Roth Capital

GT Biopharma price target lowered to $3 from $8 at Roth Capital

2026-03-02T21:36:20.000Z - 2 months ago

GT Biopharma price target lowered to $3 from $8 at Roth Capital

GT Biopharma expects cash to fund operations through Q4 2026

2026-03-02T12:12:33.000Z - 2 months ago

GT Biopharma expects cash to fund operations through Q4 2026

GT Biopharma Reports Full Year 2025 Financial Results

Mar 2, 2026, 7:00 AM EST - 2 months ago

GT Biopharma Reports Full Year 2025 Financial Results

GT Biopharma to Present at the Centurion One Capital 9th Annual Toronto Growth Conference

Feb 17, 2026, 7:30 AM EST - 3 months ago

GT Biopharma to Present at the Centurion One Capital 9th Annual Toronto Growth Conference

GT Biopharma announces FDA clearance of IND application for GTB-5550

2026-02-03T13:35:12.000Z - 3 months ago

GT Biopharma announces FDA clearance of IND application for GTB-5550

GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-5550 TriKE®, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors Expressing B7-H3

Feb 3, 2026, 8:30 AM EST - 3 months ago

GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-5550 TriKE®, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors Expressing B7-H3

GT Biopharma submits IND application to U.S. FDA for GTB-5550 TriKE

2026-01-15T13:36:22.000Z - 4 months ago

GT Biopharma submits IND application to U.S. FDA for GTB-5550 TriKE

GT Biopharma Announces IND Submission for GTB-5550 TriKE®, a B7-H3-targeted natural killer (NK) cell engager for B7-H3 expressing solid tumor cancers

Jan 15, 2026, 8:30 AM EST - 4 months ago

GT Biopharma Announces IND Submission for GTB-5550 TriKE®, a B7-H3-targeted natural killer (NK) cell engager for B7-H3 expressing solid tumor cancers

Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030

Dec 19, 2025, 7:44 AM EST - 5 months ago

Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030

GT Biopharma, Inc. (NASDAQ:GTBP) Offers Near-Term Catalyst Opportunity with Advancing Phase 1 Trials

Nov 19, 2025, 8:00 AM EST - 6 months ago

GT Biopharma, Inc. (NASDAQ:GTBP) Offers Near-Term Catalyst Opportunity with Advancing Phase 1 Trials

GT Biopharma price target lowered to $8 from $11 at Roth Capital

2025-11-17T13:10:48.000Z - 6 months ago

GT Biopharma price target lowered to $8 from $11 at Roth Capital

GT Biopharma reports Q3 net loss $3.1M vs $3.4M last year

2025-11-14T14:05:16.000Z - 6 months ago

GT Biopharma reports Q3 net loss $3.1M vs $3.4M last year

GT Biopharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 14, 2025, 9:00 AM EST - 6 months ago

GT Biopharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update

GT Biopharma files to sell 14.59M shares of common stock for holders

2025-10-24T20:20:16.000Z - 7 months ago

GT Biopharma files to sell 14.59M shares of common stock for holders

GT Biopharma provides enrollment update on GTB-3650 Phase 1 Trial

2025-10-08T13:10:29.000Z - 7 months ago

GT Biopharma provides enrollment update on GTB-3650 Phase 1 Trial

GT Biopharma Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 5, 2025, 7:00 AM EDT - 8 months ago

GT Biopharma Transcript: H.C. Wainwright 27th Annual Global Investment Conference

GT Biopharma Reports Second Quarter 2025 Financial Results

Aug 14, 2025, 4:05 PM EDT - 9 months ago

GT Biopharma Reports Second Quarter 2025 Financial Results

GT Biopharma advances into cohort 3 of GTB-3650 Phase 1 trial

2025-08-11T11:21:57.000Z - 9 months ago

GT Biopharma advances into cohort 3 of GTB-3650 Phase 1 trial

GT Biopharma Advances into Cohort 3 of GTB-3650 Phase 1 Trial Following Safety Review of Cohort 2

Aug 11, 2025, 7:00 AM EDT - 9 months ago

GT Biopharma Advances into Cohort 3 of GTB-3650 Phase 1 Trial Following Safety Review of Cohort 2

GT Biopharma appoints Mun-Gavin to board of directors

2025-06-13T13:10:35.000Z - 11 months ago

GT Biopharma appoints Mun-Gavin to board of directors

GT Biopharma Appoints New Member to its Board of Directors

Jun 13, 2025, 9:00 AM EDT - 11 months ago

GT Biopharma Appoints New Member to its Board of Directors

GT Biopharma files to sell 120.55M shares of common stock for holders

2025-06-11T21:40:29.000Z - 11 months ago

GT Biopharma files to sell 120.55M shares of common stock for holders

GT Biopharma advances GTB-3650 Phase 1 trial to Cohort 2

2025-05-19T13:10:50.000Z - 1 year ago

GT Biopharma advances GTB-3650 Phase 1 trial to Cohort 2

GT Biopharma Advances GTB-3650 Phase 1 Trial to Cohort 2 Following Successful Initial Human Dosing and Evidence of Early Immune Activation Signals

May 19, 2025, 9:00 AM EDT - 1 year ago

GT Biopharma Advances GTB-3650 Phase 1 Trial to Cohort 2 Following Successful Initial Human Dosing and Evidence of Early Immune Activation Signals

GT Biopharma appoints Andrew Ritter to board of directors

2025-05-15T13:16:23.000Z - 1 year ago

GT Biopharma appoints Andrew Ritter to board of directors

GT Biopharma appoints Kramer to board of directors

2025-05-14T11:32:30.000Z - 1 year ago

GT Biopharma appoints Kramer to board of directors

GT Biopharma files to sell 625,283 shares of common stock for holders

2025-03-06T22:25:27.000Z - 1 year ago

GT Biopharma files to sell 625,283 shares of common stock for holders

GT Biopharma Announces Exercise of Warrants

Feb 25, 2025, 2:00 PM EST - 1 year ago

GT Biopharma Announces Exercise of Warrants

GT Biopharma could report Phase 1 trial data later this year, says Roth MKM

2025-02-25T17:40:40.000Z - 1 year ago

GT Biopharma could report Phase 1 trial data later this year, says Roth MKM

GT Biopharma announces request for withdrawal of Form S-1 registration statement

2025-02-25T12:30:51.000Z - 1 year ago

GT Biopharma announces request for withdrawal of Form S-1 registration statement

GT Biopharma announces first patient dosed in Phase 1 trial of GTB-3650

2025-01-27T12:12:13.000Z - 1 year ago

GT Biopharma announces first patient dosed in Phase 1 trial of GTB-3650

GT Biopharma Reports Third Quarter 2024 Financial Results

Nov 14, 2024, 4:00 PM EST - 1 year ago

GT Biopharma Reports Third Quarter 2024 Financial Results

GT Biopharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

Sep 26, 2024, 9:15 AM EDT - 1 year ago

GT Biopharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

GT Biopharma to Host Virtual KOL Event Showcasing its NK Cell Engager Pipeline and Broad Indication Potential on October 10, 2024

Sep 24, 2024, 9:15 AM EDT - 1 year ago

GT Biopharma to Host Virtual KOL Event Showcasing its NK Cell Engager Pipeline and Broad Indication Potential on October 10, 2024

GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-3650, an NK Cell Engager for Treatment of CD33+ Leukemia

Jun 27, 2024, 9:15 AM EDT - 2 years ago

GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-3650, an NK Cell Engager for Treatment of CD33+ Leukemia

GT Biopharma, Inc. Announces $3.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

May 21, 2024, 9:15 AM EDT - 2 years ago

GT Biopharma, Inc. Announces $3.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

What made GT Biopharma stock more than double on Monday?

May 20, 2024, 10:43 AM EDT - 2 years ago

What made GT Biopharma stock more than double on Monday?

GT Biopharma Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 15, 2024, 5:00 PM EDT - 2 years ago

GT Biopharma Reports First Quarter 2024 Financial Results and Provides Corporate Update

GT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial Results

Mar 26, 2024, 5:00 PM EDT - 2 years ago

GT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial Results

GT Biopharma, Inc. Announces 1-for-30 Reverse Stock Split

Feb 1, 2024, 11:00 AM EST - 2 years ago

GT Biopharma, Inc. Announces 1-for-30 Reverse Stock Split

Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend GT Biopharma Stockholders Vote “FOR” All Proposed Items at the Upcoming Special Meeting of Stockholders

Dec 6, 2023, 9:30 AM EST - 2 years ago

Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend GT Biopharma Stockholders Vote “FOR” All Proposed Items at the Upcoming Special Meeting of Stockholders

GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia

Dec 4, 2023, 9:30 AM EST - 2 years ago

GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia

GT Biopharma Presented Positive Preclinical Data for GTB-5550, a Novel TriKE® Molecule for Targeted Prostate Cancer Treatment During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

Nov 6, 2023, 9:30 AM EST - 2 years ago

GT Biopharma Presented Positive Preclinical Data for GTB-5550, a Novel TriKE® Molecule for Targeted Prostate Cancer Treatment During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

GT Biopharma Reports Third Quarter 2023 Financial Results

Nov 1, 2023, 9:00 AM EDT - 2 years ago

GT Biopharma Reports Third Quarter 2023 Financial Results

GT Biopharma Reports Second Quarter 2023 Financial Results

Aug 7, 2023, 9:00 AM EDT - 3 years ago

GT Biopharma Reports Second Quarter 2023 Financial Results

GT Biopharma to Participate in the H.C. Wainwright Immune Cell Engager Conference on August 17, 2023

Aug 3, 2023, 1:25 PM EDT - 3 years ago

GT Biopharma to Participate in the H.C. Wainwright Immune Cell Engager Conference on August 17, 2023

GT Biopharma Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 15, 2023, 5:00 PM EDT - 3 years ago

GT Biopharma Reports First Quarter 2023 Financial Results and Provides Corporate Update

GT Biopharma Names Charles J. Casamento to the Board of Directors

May 4, 2023, 9:05 AM EDT - 3 years ago

GT Biopharma Names Charles J. Casamento to the Board of Directors

GT Biopharma Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update

Mar 30, 2023, 5:00 PM EDT - 3 years ago

GT Biopharma Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update

GT Biopharma to Participate in the H.C. Wainwright Cell Therapy Virtual Conference

Feb 24, 2023, 9:00 AM EST - 3 years ago

GT Biopharma to Participate in the H.C. Wainwright Cell Therapy Virtual Conference

GT Biopharma Issues Open Letter to Shareholders Detailing Recent Activities

Feb 2, 2023, 9:46 AM EST - 3 years ago

GT Biopharma Issues Open Letter to Shareholders Detailing Recent Activities

GT Biopharma, Inc. Announces $6.5 Million Registered Direct Offering Priced At Premium To Market

Dec 30, 2022, 8:00 AM EST - 3 years ago

GT Biopharma, Inc. Announces $6.5 Million Registered Direct Offering Priced At Premium To Market

GT Biopharma Names Dr. Jeff Miller as Consulting Chief Medical Officer

Dec 14, 2022, 7:30 AM EST - 3 years ago

GT Biopharma Names Dr. Jeff Miller as Consulting Chief Medical Officer

GT Biopharma and Fate Therapeutics Present Preclinical Data Highlighting Novel Dual Antigen Targeting Approach For The Treatment of AML at ASH 2022

Dec 12, 2022, 7:30 AM EST - 3 years ago

GT Biopharma and Fate Therapeutics Present Preclinical Data Highlighting Novel Dual Antigen Targeting Approach For The Treatment of AML at ASH 2022

GT Biopharma Presents Two Posters at the Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting

Nov 10, 2022, 3:15 PM EST - 3 years ago

GT Biopharma Presents Two Posters at the Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting

GT Biopharma to Present New Data on Novel Dual-Antigen Targeting Approach Against AML at Upcoming 2022 ASH Annual Meeting

Nov 3, 2022, 9:00 AM EDT - 3 years ago

GT Biopharma to Present New Data on Novel Dual-Antigen Targeting Approach Against AML at Upcoming 2022 ASH Annual Meeting

GT Biopharma Reports Third Quarter Fiscal 2022 Financial Results and Business Update

Oct 31, 2022, 5:15 PM EDT - 3 years ago

GT Biopharma Reports Third Quarter Fiscal 2022 Financial Results and Business Update

GT Biopharma Presents at LD Micro on October 26, 2022 at 4:30 pm PST

Oct 25, 2022, 2:44 PM EDT - 3 years ago

GT Biopharma Presents at LD Micro on October 26, 2022 at 4:30 pm PST

GT Biopharma Announces Two Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting

Oct 6, 2022, 8:18 AM EDT - 3 years ago

GT Biopharma Announces Two Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting

GT Biopharma Announces Adjournment of Special Shareholders Meeting

Oct 4, 2022, 4:10 PM EDT - 3 years ago

GT Biopharma Announces Adjournment of Special Shareholders Meeting

GT Biopharma Poster Presentation and Mini Oral Session at ESMO Congress 2022 Demonstrates GTB-5550 TriKE® Ability to Specifically Target and Efficiently Kill Multiple B7H3+ Solid and Hematologic Malignancies

Sep 12, 2022, 9:34 AM EDT - 3 years ago

GT Biopharma Poster Presentation and Mini Oral Session at ESMO Congress 2022 Demonstrates GTB-5550 TriKE® Ability to Specifically Target and Efficiently Kill Multiple B7H3+ Solid and Hematologic Malignancies

GT Biopharma to Participate in the H.C. Wainwright 24th Annual Global Investment Conference in September

Sep 8, 2022, 7:30 AM EDT - 3 years ago

GT Biopharma to Participate in the H.C. Wainwright 24th Annual Global Investment Conference in September

GT Biopharma Affirms Manufacturing Timeline For Lead Investigational Asset GTB-3650

Aug 30, 2022, 6:00 PM EDT - 4 years ago

GT Biopharma Affirms Manufacturing Timeline For Lead Investigational Asset GTB-3650

GT Biopharma Reports Second Quarter Fiscal 2022 Financial Results and Business Update

Aug 11, 2022, 9:35 AM EDT - 4 years ago

GT Biopharma Reports Second Quarter Fiscal 2022 Financial Results and Business Update

GT Biopharma Presents Preclinical Data Demonstrating Second-Generation CD19 Targeting Tri-Specific Killer Engager (TriKE®) Driving Robust NK Cell Function Against B Cell Malignancies at EHA 2022 Congress

Jun 10, 2022, 8:00 AM EDT - 4 years ago

GT Biopharma Presents Preclinical Data Demonstrating Second-Generation CD19 Targeting Tri-Specific Killer Engager (TriKE®) Driving Robust NK Cell Function Against B Cell Malignancies at EHA 2022 Congress

GT Biopharma Reports First Quarter Fiscal 2022 Financial Results and Business Update

May 16, 2022, 8:01 AM EDT - 4 years ago

GT Biopharma Reports First Quarter Fiscal 2022 Financial Results and Business Update

GT Biopharma to Participate at H.C. Wainwright Hybrid Global Investment Conference

May 12, 2022, 8:00 AM EDT - 4 years ago

GT Biopharma to Participate at H.C. Wainwright Hybrid Global Investment Conference

GT Biopharma Presents Preclinical Data Demonstrating Novel B7H3+ Tumor Targeting GTB-5550 TriKE® Driving NK Cell Activation and ADCC Against Head and Neck Squamous Cell Carcinomas at AACR Annual Meeting 2022

Apr 11, 2022, 7:30 AM EDT - 4 years ago

GT Biopharma Presents Preclinical Data Demonstrating Novel B7H3+ Tumor Targeting GTB-5550 TriKE® Driving NK Cell Activation and ADCC Against Head and Neck Squamous Cell Carcinomas at AACR Annual Meeting 2022

GT Biopharma Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update

Mar 28, 2022, 4:15 PM EDT - 4 years ago

GT Biopharma Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update

Investing4Knowledge
Investing4Knowledge May. 5 at 1:53 PM
$SRXH - those who wait will be rewarded here, just like $GTBP which was dormant and now finally taking up the last couple days
1 · Reply
princedazzler
princedazzler May. 4 at 5:44 PM
$GTBP Has great volume Should rip sometime soon Wuld be great to rip to $14
1 · Reply
Sidd_F
Sidd_F May. 4 at 5:36 PM
$GTBP if you've ever been curious about Cataldo's abrupt departure... https://hannahhowell.com/anthony-cataldo-stole-3-2m-from-gt-biopharma-to-fund-his-beverly-hills-mansion/
1 · Reply
vesti
vesti May. 4 at 4:52 PM
$GTBP Probably shorties margin calls.
0 · Reply
WallStreetVice
WallStreetVice May. 3 at 7:26 PM
$GTBP Need a bounce to 1$
0 · Reply
BillionerOfKing
BillionerOfKing May. 2 at 12:39 AM
$GTBP Current Stock Price: $0.34
0 · Reply
Zulu72
Zulu72 May. 1 at 2:12 PM
$GTBP first decent price action in weeks ... cant find any news ... anybody know anything? 😬
0 · Reply
Investing4Knowledge
Investing4Knowledge Apr. 27 at 6:34 PM
$GTBP - crazy sell off for zero reason. Looking forward to the company releasing PR updates here. If everything goes as planned, I could see this getting back to $0.80-$1.00 range
1 · Reply
vesti
vesti Apr. 24 at 3:45 PM
$GTBP upgraded to buy by Zacks https://www.zacks.com/stock/news/2884714/gt-biopharma-gtbp-upgraded-to-buy-here-s-what-you-should-know?cid=CS-STOCKTWITS-HL-tale_of_the_tape|yseop_template_12_zacks_rank_upgrade-2884714&adid=SYND_STOCKTWITS_HEADLINE_TALEOFTHETAPE_523_2884714
0 · Reply
focafoca99
focafoca99 Apr. 7 at 9:12 PM
$GTBP entered an investigator-sponsored clinical-trial agreement with the University of Minnesota for GTB-5550 worth up to about $3.8 million over three years.
0 · Reply
Dr_Monkeybreath
Dr_Monkeybreath Apr. 2 at 7:06 PM
$GTBP still here. 😶‍🌫️
1 · Reply
Investing4Knowledge
Investing4Knowledge Apr. 2 at 6:54 PM
$GTBP ->I sense $0.50+ in the near future here and $0.18+ in the near future here -> $SRXH Keep them on watch 👀
0 · Reply
Waterwing
Waterwing Apr. 1 at 2:36 PM
$GTBP
0 · Reply
kim46
kim46 Mar. 29 at 4:28 PM
$GTBP $IBRX say it again
0 · Reply
kim46
kim46 Mar. 29 at 4:27 PM
$GTBP $IBRX Folk are finally catching on. They will ride the coattail of IBRX. The stock price is cheapppppp! Load the boat
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 27 at 12:52 PM
$GTBP RSI: 44.50, MACD: -0.0157 Vol: 0.02, MA20: 0.45, MA50: 0.52 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Kaynoshi
Kaynoshi Mar. 26 at 9:20 AM
$GTBP 👈 ✅ $IBRX
0 · Reply
kellymone2
kellymone2 Mar. 26 at 9:10 AM
$GTBP hello everybody, what do you expect here? RS or news that bring back the stock above 1$?
0 · Reply
BarryLong28
BarryLong28 Mar. 24 at 7:34 PM
$GTBP
0 · Reply
Kaynoshi
Kaynoshi Mar. 24 at 2:51 PM
$GTBP 👈 ✅ $IBRX
0 · Reply